Bispecific Antibodies Enable Safer Cancer Therapy Through Tumor-Selective Targeting Strategies

Introduction

Many cancer therapies fail to achieve their full potential because the molecular targets driving tumor growth are also essential for normal tissue function. Blocking pathways such as Wnt, EGFR, or FGFR1 can effectively inhibit tumors but often causes severe toxicity in healthy organs.

A recent study published in Science Advances introduced a new approach using tumor-targeted bispecific antibodies (bsAbs) to overcome this challenge. By combining a weakly active therapeutic antibody arm with a high-affinity tumor-specific targeting arm, this strategy enables selective pathway inhibition within tumor cells while minimizing damage to normal tissues.

Tumor-Selective Activation Through Bispecific Antibody Design

Traditional antibody therapies usually require targets to be highly tumor-specific, which limits the number of druggable targets. The new strategy takes a different approach:

• One antibody arm binds an oncogenic receptor with intentionally reduced affinity.
• The second arm recognizes a tumor-enriched surface marker.
• Dual binding increases local antibody concentration on tumor cells through avidity effects.
• Normal cells lacking the tumor marker remain largely unaffected.

Using single-cell RNA sequencing (scRNA-seq), researchers identified tumor-enriched receptors that were absent from vulnerable normal cell populations, enabling selective targeting.

Engineering Safer Inhibition of Oncogenic Pathways

1. Targeting Wnt Signaling in Pancreatic Cancer

The Wnt pathway is a promising cancer target but has been difficult to inhibit due to intestinal toxicity.

Researchers developed an attenuated anti-FZD antibody variant with reduced binding activity. When combined with tumor-targeting arms against TROP2 or CEACAM6, the bispecific antibodies restored strong anti-tumor activity in pancreatic cancer models.

Key findings include:

• Effective suppression of Wnt pathway genes in tumors
• Strong growth inhibition in pancreatic cancer cells and organoids
• Minimal intestinal damage compared with conventional FZD inhibitors

2. Expanding the Platform to EGFR and FGFR1

The tumor-targeting bispecific antibody strategy was also applied to other clinically important pathways.

For FGFR1:

• Tumor cells expressing the anchor receptor were selectively inhibited.
• Kidney cells responsible for FGFR-related toxicity remained unaffected.

For EGFR:

• CEACAM6-targeted antibodies maintained strong activity against cancer cells.
• Normal keratinocytes showed substantially reduced sensitivity compared with traditional EGFR inhibitors.

These results demonstrate that the platform can be adapted across multiple cancer targets.

Mechanism Beyond Simple Avidity

Further analysis revealed that improved activity was not only caused by stronger binding. Co-engagement of tumor receptors promoted receptor internalization, effectively removing target molecules from the cell surface.

For FZD-targeted antibodies, this process:

• Accelerated receptor uptake
• Reduced Wnt ligand signaling
• Triggered tumor-selective pathway inhibition

This mechanism allows antibodies with limited standalone activity to become powerful therapeutic molecules when properly targeted.

Conclusion

Tumor-selective bispecific antibodies represent a new generation of precision oncology strategies. Instead of requiring completely tumor-specific targets, this approach uses differences in receptor expression between tumors and healthy tissues to create a wider therapeutic window.

By integrating single-cell sequencing, antibody engineering, and targeted delivery strategies, researchers can transform previously limited cancer targets into viable therapeutic opportunities. This concept provides a promising direction for developing safer and more effective antibody-based cancer treatments.